Vopratelimab (Mouse IgG2a)

Cat. No.: HY-P99382A: Data Sheet
FAQs
Technical Support

Vopratelimab (Mouse IgG2a) is a monoclonal antibody that selectively targets Inducible CO-Stimulator of T cells (ICOS). The variable region of Vopratelimab (Mouse IgG2a) is consistent with that of Vopratelimab (HY-P99382), while the constant region is of Mouse IgG2a sequence. Vopratelimab (Mouse IgG2a) has antitumor immune response and enhances combinatorial efficacy with anti-PD-1 (HY-P9902A) therapy.

For research use only. We do not sell to patients.

Vopratelimab (Mouse IgG2a) Chemical Structure

Size		Stock
MOQ		Minimum order quantity
1 mg		Get quote
5 mg		Get quote
10 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Vopratelimab (Mouse IgG2a):

Vopratelimab In-stock

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vivo

Aducanumab (Mouse IGG2a) (0.25-0.3  mg/kg, i.p., 4 doses at 7, 10, 14 and 17 days) has significant anti-tumor activity (70% tumor regression) with a systemic long-term immunity in the Sa1/N fibrosarcoma mice model^[1].
Aducanumab (Mouse IGG2a) (0.25 mg/kg, i.p., 2 doses at 6 and 11 days) has significant anti-tumor activity with long-term protection in B16-SIY tumor mice model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female A/J mice (6-8 weeks old) were injected subcutaneously with Sa1/N cells (1 × 10⁶ cells/mouse) to induce Sa1/N fibrosarcoma mice model^[1].
Dosage:	0.25-0.3 mg/kg
Administration:	i.p., 4 doses (7, 10, 14 and 17 days) for 11 days after tumors reaching approximately 100 mm³.
Result:	Had significant anti-tumor activity with 7 out of 10 mice showing complete tumor regression. Induced systemic long-term immunity with re-challenge with Sa1/N tumors ~45 days after the last treatment in Tumor-free mice. Decreased the percentage of intratumoral CD4⁺FoxP3⁺ Treg within CD3⁺ cells, but increased in the CD8: Treg and CD4 Teff: Treg ratios in the tumors.

Animal Model:	Mice were injected subcutaneously with B16-SIY cells to induce B16-SIY tumor mice model^[1].
Dosage:	0.25 mg/kg
Administration:	i.p., 6 and 11 days
Result:	Induced no tumor growth and survived re-challenge with B16-SIY tumors 10 weeks. Induced T cells proliferation in both peripheral blood and spleen and tetramer+ T cells proliferation in spleen as well as the frequency of activated memory CD8 T cells. Induced Treg depletion and increased effector T cell to Treg ratios.

SMILES

[Vopratelimab (Mouse IgG2a)]

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Inhibitory Antibodies User Guide (602 KB)

References

[1]. Hanson A, et al. ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models. PLoS One. 2020 Sep 24;15(9):e0239595. [Content Brief]